CD20-directed Cytolytic Antibody [EPC]

329764 reported adverse events

Drugs of this class: OBINUTUZUMAB OCRELIZUMAB OCRELIZUMAB AND HYALURONIDASE OFATUMUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR UBLITUXIMAB

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

#	Side effect	Count
0	OFF LABEL USE	48465
1	DRUG INEFFECTIVE	38216
2	FATIGUE	29935
3	PAIN	24432
4	COVID-19	21131
5	RHEUMATOID ARTHRITIS	20406
6	HEADACHE	18473
7	PYREXIA	18241
8	INFUSION RELATED REACTION	17411
9	PNEUMONIA	17059

See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	5793	0.8258
1	VACCINE INTERACTION	241	0.7876
2	PEMPHIGUS	9436	0.7689
3	SWOLLEN JOINT COUNT INCREASED	2339	0.7597
4	RED BLOOD CELL SEDIMENTATION RATE	211	0.7590
5	SARS-COV-2 ANTIBODY TEST NEGATIVE	358	0.7537
6	RHEUMATIC FEVER	3221	0.7470
7	RHEUMATOID FACTOR POSITIVE	4203	0.7381
8	B-LYMPHOCYTE COUNT DECREASED	980	0.7368
9	C-REACTIVE PROTEIN	649	0.7243

See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]